Aurinia Pharmaceuticals (AUPH) Posts Wider Q2 Loss

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.26), $0.12 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $29 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Aspire Biopharma to acquire automotive supplier for $30 million